Prrooviding You with the Tools, Sservice
Total Page：16
File Type：pdf, Size：1020Kb
Load more
Recommended publications
-
Donation Needs Fluctuate Loc Products, Hair Wraps and Bonnets, Spray Bottles) Throughout the Year
DONATION UPDATED MARCH 2020 NEEDS ONGOING NEEDS DONATION GUIDELINES General hygiene items (Lotion, face wash, toilet paper, YWCA only accepts new, unused, unopened and body wash, lip balm, bar soap, hand soap, tissues) unexpired donations. We do not have the space or staff capacity to sort through and store used Hair products (Shampoo, conditioner, haircut gift cards, items. We also ask that you donate full-sized items, hair ties, combs, brushes, leave-in conditioner, hair styling especially in regards to toiletries. Please call for products) the most up to date information regarding our donation policies and/or current needs. Hair care products for people of color (Most requested brands: Cantu, Shea Moisture, Carol’s Daughter, Maui Moisture, Form, Biosilk, Tgin, Miss Jessie’s, Aunt Jackie’s, DONATION DRIVES Taliah Waajid - Products: shampoos, conditioners, hair gel, Does your group or organization want to host a oils, shea butter, hair brushes, hair mousse, hair custard, donation drive? Our donation needs fluctuate loc products, hair wraps and bonnets, spray bottles) throughout the year. To ensure your hard work Menstural care items (Pads and liners) meets the needs of our clients, please contact us to find out what donation items are in limited Feminine hygiene items (Deodorant, razors, shaving supply at the time of your planned drive! cream, underwear) ACCEPTING DONATIONS Masculine hygiene items (Razors, shaving cream, deodorant, body spray, 3-in-1 products, hair styling Donations are accepted at our administrative products, underwear) offices located at405 Broadway on Monday through Thursday, 8:30 am to 5:30 pm and Friday, Dental hygiene items (Toothbrushes of all sizes, 8:30 am to 4:30 pm. -
2021 SELECT EX FORMULARY the Following Is a List of the Most Commonly Prescribed Brand and Generic Medications
2021 SELECT EX FORMULARY The following is a list of the most commonly prescribed brand and generic medications. It represents an abbreviated version of the formulary list that is at the core of your prescription drug benefit plan. The list is not all-inclusive and does not guarantee coverage. Some preferred medications overlap with other clinical programs and may not be covered. In addition to drugs on this list, the majority of generic medications are covered under your plan and you are encouraged to ask your doctor to prescribe generic drugs whenever appropriate. Search complete formulary drug information at elixirsolutions.com. PLEASE NOTE: Preferred brand drugs may move to non-preferred status if a generic version becomes available during the year. Any medication approved to enter the market will not be covered until reviewed by Elixir. Not all drugs listed are covered by all prescription drug benefit programs. For specific questions about your coverage, please visit elixirsolutions.com. A B CILOXAN OINTMENT digoxin abacavir tablet balsalazide CIMDUO diltiazem ER (except generics for abacavir-lamivudine BAQSIMI cinacalcet CARDIZEM LA) ABILIFY MAINTENA [INJ] BASAGLAR [INJ] ciprofloxacin dimethyl fumarate DR* abiraterone* BD ULTRAFINE INSULIN SYRINGES ciprofloxacin-dexamethasone diphenoxylate-atropine acetic acid & NEEDLES citalopram dipyridamole ER-aspirin acitretin BELBUCA CITRANATAL divalproex sodium ACUVAIL BELSOMRA clarithromycin divalproex sodium ER acyclovir capsule, tablet benzonatate (except NDCs: clarithromycin ER DIVIGEL -
IN THIS ISSUE General Assembly Judiciary Regulations Errata Special Documents General Notices
Issue Date: May 26, 2017 Volume 44 • Issue 11 • Pages 513—574 IN THIS ISSUE General Assembly Judiciary Regulations Errata Special Documents General Notices Pursuant to State Government Article, §7-206, Annotated Code of Maryland, this issue contains all previously unpublished documents required to be published, and filed on or before May 8, 2017, 5 p.m. Pursuant to State Government Article, §7-206, Annotated Code of Maryland, I hereby certify that this issue contains all documents required to be codified as of May 8, 2017. Gail S. Klakring Acting Administrator, Division of State Documents Office of the Secretary of State Information About the Maryland Register and COMAR MARYLAND REGISTER HOW TO RESEARCH REGULATIONS The Maryland Register is an official State publication published An Administrative History at the end of every COMAR chapter gives every other week throughout the year. A cumulative index is information about past changes to regulations. To determine if there have published quarterly. been any subsequent changes, check the ‘‘Cumulative Table of COMAR The Maryland Register is the temporary supplement to the Code of Regulations Adopted, Amended, or Repealed’’ which is found online at Maryland Regulations. Any change to the text of regulations http://www.dsd.state.md.us/PDF/CumulativeTable.pdf. This table lists the published in COMAR, whether by adoption, amendment, repeal, or regulations in numerical order, by their COMAR number, followed by the emergency action, must first be published in the Register. citation to the Maryland Register in which the change occurred. The The following information is also published regularly in the Maryland Register serves as a temporary supplement to COMAR, and the Register: two publications must always be used together. -
A Concise Guide to Treating Painful Oral Lesions
Drugs Used to Treat Osteoporosis and Bone Cancer Perio & Implant Centers The Team for of the Monterey Bay (831) 648-8800 Jochen P. Pechak, DDS, MSD in Silicon Valley (408) 738-3423 Which May Cause Osteonecrosis of the Jaws mobile: www.DrPechakapp.com he many bisphosphonates and monoclonal antibodies which are used to treat osteoporosis and bone cancer often web: GumsRus.com causeDrugsDrugs osteonecrosis Used Used of the to jaws.to Treat AsTreat dental clinicians,Osteoporosis Osteoporosis it is important that and andwe are Bone awareBone of this Cancers Cancers side effect before Ttreating our patients who are taking these drugs. The tables below summarize these drugs, the route these drugs are administered, andWhich Whichtheir likelihood May May of causing Cause Cause osteonecrosis Osteonecrosis Osteonecrosis of the jaws as reported byof of Dr. the theRobert Jaws JawsMarx at the University of Miami Division of Oral and Maxillofacial Surgery. PDL tm Osteoporosis Drugs Drugs Osteoporosis Used to Treat Drugs Osteoporosis PerioDontaLetter Jochen P. Pechak, DDS, MSD, Periodontics and Implant Dentistry Spring DrugDrug ClassificationClassification ActionAction DoseDose RouteRoute %% of of ReportedReported CasesCases of of OsteonecrosisOsteonecrosis AlendronateAlendronate BisphosphonateBisphosphonate OsteoclastOsteoclast 7070 mg/wk mg/wk OralOral 8282%% From Our Office A Concise Guide to Treating (Fosamax(Fosamax ToxicityToxicity to Yours... Generic)Generic) Painful Oral Lesions ResidronateResidronate BisphosphonateBisphosphonate OsteoclastOsteoclast 3535 mg/wk mg/wk OralOral 1%1% As dentists specializing in treat- (Actonel Toxicity (Actonel Toxicity ment of diseases of the oral cavity atients present frequently with Treating Cold Sores Atelvia)Atelvia) and associated structures, we are painful oral lesions. They are often also called upon to treat pain- IbandronateIbandronate BisphosphonateBisphosphonate OsteoclastOsteoclast 150150 mg/mos mg/mos OralOral 1%1% usually not serious, but patients And Canker Sores (Boniva) Toxicity IV ful oral lesions in the mouth. -
Making an Elderberry Syrup Or Elixir
Making an Elderberry Syrup or Elixir Herbal syrups are water extractions of herbs (usually decoctions—see below) that are concentrated with a sweetener (preferably organic white sugar or raw honey). This sweetener provides a bit of nutritional support as a carbohydrate and also acts as a preservative. The concentration of sugar is particularly important when making syrups and elixirs; when in water, sugar acts as a food source for micro-organisms (especially molds and yeasts). However, at a high enough concentration, the sugar actually restricts the growth ability of micro-organisms. So we are aiming to get our syrup to be saturated enough to preserve, but not so saturated that the sugar overwhelms the liquid and causes crystallization. When preparing a syrup, one of the following ratios should be used: 1 part decoction : 1 part sweetener 1 part decoction : 2 parts sweetener I tend to follow the 1 part water : 1 part sweetener suggestion, as the 1 : 2 ratio is too sweet for me. But I have access to a refrigerator, which will also help with preservation. If you are keeping your syrup at room temperature, the 1:2 ratio is best. Syrups are a great, palatable method for delivery of herbal medicines (especially for children), and are also a great way to mask the flavor of less tasty tinctures--just combine the tincture and the syrup and you get the medicinal benefits of both. Preserving syrups with honey is also a great way to combine the medicinal benefits of the honey with the herbs that are being used. Do not give syrups preserved with honey to children under the age of one. -
Slang Terms and Jargon Can Cause Medication Errors
Volume 19, Number 10 November/December 2005 Drugs & Therapy B � U � L � L � E � T � I � N MEDICATION SAFETY FORMULARY UPDATE The Pharmacy and Therapeutics Slang terms and jargon can Committee met October 18, 2005. 4 products were added in the Formulary cause medication errors and 2 were deleted. 1 dosage form was evaluated and designated nonformu- his month “Magic Mouthwash” ents. An allergy screen would not be lary and not available, and 2 drugs T was deleted from the Formulary done, unless the individual ingredients were evaluated, but not added. Criteria (see Formulary Update). The P&T are appreciated. for use were modifi ed for 3 drugs. Committee took this action for medica- Magic Mouthwash will no longer be tion safety reasons. This continues the dispensed at Shands UF because there ◆ ADDED policy of not allowing the use of non- is no evidence that it works better than specifi c terms for mixtures that have a plain saline rinse. Clozapine Tablets traditionally been used. This action follows the banning of (generic by IVAX) Terms like “Magic Mouthwash” are the term “Butt Paste” several years Glutaraldehyde 0.6% Solution slang, jargon, or coined phrases for ago. Like Magic Mouthwash, Butt Paste (compounded) mixtures that have a specifi c purpose. is a nonspecifi c mixture of ingredients. Levofl oxacin In this instance, the “magic” is pain The “Butt Paste” mixture contained (Levaquin® by Ortho McNeil)* reduction in patients who have muco- Questran Light® (cholestyramine) in sitis of the mouth. Mucositis is a very Aquaphor®. The theory is that the cho- Ondansetron Tablets ® painful condition in patients receiving lestyramine binds bile acids that may (Zofran by GlaxoSmithKline) aggressive cytotoxic chemotherapy. -
Pharmacy Manual Supplemental Policies, Procedures and Regulations
Last revision date: 12.17.2020 Pharmacy Manual Supplemental Policies, Procedures and Regulations Prepared by: Elixir 800-361-4542 ELIXIRSOLUTIONS.COM 2181 E. Aurora Road, Suite 201 | Twinsburg, OH 44087 Copyright © 2020, Elixir. All rights reserved. Version 41 *This page was intentionally left blank* 1 Table of Contents PHARMACY MANUAL INTRODUCTION......................................................................................................................... 5 GENERAL INFORMATION ............................................................................................................................................. 5 PROPRIETARY AND CONFIDENTIAL .................................................................................................................. 5 ADVERTISING REQUESTS .............................................................................................................................. 6 CONTACT INFORMATION / WHERE TO GET HELP ...................................................................................................... 6 NETWORK ENROLLMENT FORM AND CREDENTIALING GUIDELINES ....................................................................... 6 APPLYING FOR PARTICIPATION ...................................................................................................................... 6 CREDENTIALING AND RECREDENTIALING GUIDELINES ....................................................................................... 7 PROVIDER AND MEMBER SERVICE STANDARDS ..................................................................................................... -
Epinephrine Auto-Injector
ELIXIR; Epinephrine Auto-Injector FINAL DESIGN & PRODUCT SPECIFICATION REPORT DNH603_SEM2 Zoe Avgoustakis n8607912 CONTENTS 1. Introduction 2. Final Product Design 2.1 Description 2.2 Usability 2.3 QoI Table / Product Ecosystem 3. Value Proposition , 4. Design Justification 4.1 Mechanism 4.2 Form 4.3 Usability 5. Technical Documentation 5.1 Product Components 5.2 Product Function 5.3 Specifications 5.4 Standards 5.5 B.O.M Technical Drawings DNH603_16se2 : i-move project Epinephrine Auto-injector Zoe Avgoustakis n8607923 0.03mg Adrenaline 1. INTRODUCTION Over the course of this project, imm-you-nity has worked to provide innovative design solutions focused on interactive interfaces and devices to help people be more aware, in control and engaged with their health and wellness. The project aim was to design and develop a new consumer interactive product that would provide a distinct personal experience, improving the user’s management and relationship with their Health & Wellness. The project was specifically focused towards the user’s engagement with allergy conditions. Design investigation accounted for emerging technologies and how this could be applied to enhance the user’s management and interaction with severe allergies and anaphylaxis. Australia has one of the highest reported incidences of food allergies in the world with one in ten people forecasted to develop a food allergy throughout their lives. As those who obtain allergies become more and more prevalent, people are turning to technology for assitance of this issue. The client approached the team in endeavour to develop a product that could assist people with the management and treatment of severe allergy conditions of anaphylaxis. -
2020 PBD 5 Tier Formulary
2020 Pharmacy Benefit Dimensions 5 Tier Drug Formulary The following information applies to most members enrolled in a Pharmacy Benefit Dimensions pharmacy plan. Note: If you are reading a printed version of this drug formulary, content may have been updated since it was last printed. For the most up-to-date information, please visit www.pbdrx.com. Drug Formulary Introduction • Generic drugs appear in lower case. Brand name drugs are capitalized. • Preferred generic drugs and a few select brand name drugs are assigned to Tier 1. In most instances, once a generic product is available for which there are no bioequivalence concerns, the brand product is removed from the formulary (not covered), and the generic product is assigned to Tier 1. Certain generic drugs may also be covered in a non-preferred tier when efficacy, safety, or cost factors suggest that better alternatives exist on the formulary. • Pharmacy Benefit Dimensions reserves the right to modify drug tiers as necessary. • Some medications are considered non-formulary (not covered). To obtain a medication that is non-formulary, your health care provider is encouraged to submit a Prior Authorization request for coverage through the exception process. If the request is approved, you will be responsible for the cost share associated with a non- preferred drug tier. • Certain self-funded employer groups may not follow this base formulary and certain exclusions may apply. Members in these pharmacy benefit management groups should refer to their summary plan description and/or their benefit administrator. Prior-Authorization Prior Authorization is required for certain medications. To obtain coverage for a medication requiring Prior Authorization, a Prior Authorization request for medical exception must be submitted by your health care provider and approved by Pharmacy Benefit Dimensions. -
603 V7 Longdiffusercontrolfrizz the Head of a Woman with Wavy Brown
603_v7_LongDiffuserControlFrizz The head of a woman with wavy brown hair appears in front of a background of white and gold with the Pantene logo. She slowly turns in a circle, revealing her wavy hairstyle, and smiles. ON SCREEN TEXT: HOW TO diffused curls PANTENE FEMALE NARRATOR: Want to take a break from your flat iron? Try a diffuser to control frizz when heat and humidity make styling a challenge. Here's a technique that will help. Cut to a white background. Various hairstyling tools appear on-screen, including a diffuser, hair dryer, and wide-tooth comb. ON SCREEN TEXT: TOOLS you will need Diffuser Hair Dryer Wide Tooth Comb The woman combs through her wet hair with a black wide-tooth comb. A black wide-tooth comb appears at the side of the screen. ON SCREEN TEXT: 1/COMB OUT WET HAIR with a wide tooth comb NARRATOR: Start with wet hair, and comb out with a wide-tooth comb or pick. This will get rid of tangles while minimizing the breakage and split ends brushing can cause. The woman squirts hair mousse and smooth serum into her hand and applies it into her hair with her fingers. ON SCREEN TEXT: 2/COMBINE curl mousse & smooth serum NARRATOR: Now combine no-crunch curl mousse and smooth serum in your hand and distribute it through your hair. ON SCREEN TEXT: 3/DISTRIBUTE THE MIXTURE through your hair NARRATOR: The mousse will help define the curls, while the serum helps contain any flyaways, and it's great for controlling frizz. The woman attaches a diffuser to a blow-dryer and lowers a section of her hair into the diffuser, drying it. -
Adapter for Use with Aerosolization Device For
(19) TZZ_¥ ¥_T (11) EP 1 893 273 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61M 16/20 (2006.01) F16K 15/14 (2006.01) 25.06.2014 Bulletin 2014/26 (86) International application number: (21) Application number: 06824753.5 PCT/US2006/019446 (22) Date of filing: 18.05.2006 (87) International publication number: WO 2007/030162 (15.03.2007 Gazette 2007/11) (54) ADAPTER FOR USE WITH AEROSOLIZATION DEVICE FOR ENDOBRONCHIAL THERAPY ADAPTER ZUR ANWENDUNG MIT EINER AEROSOLISIERUNGSVORRICHTUNG FÜR ENDOBRONCHIALE THERAPIE ADAPTATEUR POUR L’UTILISATION AVEC UN DISPOSITIF D’AÉROSOLISATION POUR TRAITEMENT ENDOBRONCHIQUE (84) Designated Contracting States: • FISHER, Winfield AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Castro Valley, CA 94546 (US) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • COHEN, Gal SK TR San Francisco, CA 94110 (US) (30) Priority: 18.05.2005 US 682099 P (74) Representative: Boult Wade Tennant 29.09.2005 US 722637 P Verulam Gardens 70 Gray’s Inn Road (43) Date of publication of application: London WC1X 8BT (GB) 05.03.2008 Bulletin 2008/10 (56) References cited: (73) Proprietor: Nektar Therapeutics WO-A-00/12161 WO-A-98/20938 San Carlos, CA 94070 (US) WO-A-98/20938 WO-A1-02/092169 WO-A1-02/092169 AU-B2- 496 203 (72) Inventors: AU-B2- 496 203 GB-A- 2 219 844 • CECKA, Walter GB-A- 2 219 844 US-A- 4 259 951 Berkeley, CA 94705 (US) US-A- 4 259 951 US-A- 4 428 392 • ALSTON, William, W. -
Elkriterier 95/0519
Pretty Nasty – Phthalates in European Cosmetic Products Contents Executive summary 3 Actions needed 3 Abbreviations 4 Introduction 5 Materials and methods 5 Results 6 Reproductive toxicity of phthalates 11 Major pollutants and aggregate exposure 14 Regulation of phthalates in the EU 16 References 19 © November 2002 by Health Care Without Harm All rights reserved. Produced in Sweden. Contributors Joseph DiGangi, PhD Health Care Without Harm, USA Helena Norin Swedish Society for Nature Conservation, Sweden Acknowledgments Our thanks go to the following individuals who helped shape the content of this report or who served as reviewers: Charlotte Brody, Health Care Without Harm, USA; Lone Hummelshøj, Health Care Without Harm, Europe; Helen Lynn, Women’s Environmental Network, UK; Frida Olofsdotter, Swedish Society for Nature Conservation, Sweden; Per Rosander, Health Care Without Harm, Europe; Ted Schettler, MD, Science and Environmental Health Network, USA; Liz Sutton, Women’s Environmental Network, UK. Thanks also to Mera text & form for report design and production. Executive Summary Women’s Environmental Network, Swedish Society for Nature Conservation, and Health Care Without Harm contracted a certified Swedish analytical laboratory to test 34 name-brand cos- metic products for phthalates, a large family of synthetic chemicals linked to decreased fertility and reproductive defects. The laboratory found phthalates in nearly 80% of the products. More than half of the tested cosmetics contained more than one type of phthalate. Major brands included products by Boots, Christian Dior, L’Oreal, Procter & Gamble, Lever Fabergé, and Wella. None of the products listed phthalates as an ingredient on the label. In November 2002, the EU amended the Cosmetics Directive 76/768/EEC to order the removal of two phthalates in the very near future because of their reproductive toxicity (DEHP and DBP).